Indications for use
Active immunisation of dogs against Bordetella bronchiseptica and canine parainfluenza virus for periods of increased risk to reduce clinical signs induced by B. bronchiseptica and canine parainfluenza virus and to reduce shedding of canine parainfluenza virus.
Onset of immunity:
for B. bronchiseptica: 72 hours after vaccination;
for canine parainfluenza virus: three weeks after vaccination.
Duration of immunity: 1 year.
Special warnings for each target species
Only healthy dogs should be vaccinated.
Special precautions for use
Special precautions for use in animals
Vaccinated animals can spread the B. bronchiseptica vaccine strain for six weeks and the canine parainfluenza vaccine strain for a few days after vaccination.
Immunosuppressive medication may impair the development of active immunity and may increase the chance of adverse effects caused by the live vaccine strains.
Cats, pigs and unvaccinated dogs may react to the vaccine strains with mild and transient respiratory signs. Other animals, like rabbits and small rodents have not been tested.
Immunocompromised individuals should avoid any contact with the vaccine and vaccinated dogs up to six weeks after vaccination.
Disinfect hands and equipment after use.
Mild discharges from the eyes and nose can occur from the day after vaccination, sometimes accompanied by wheezing, sneezing and/or coughing, particularly in very young susceptible puppies. Signs are generally transient, but in occasional cases may persist for up to four weeks. In animals, which show more severe signs, appropriate antibiotic treatment may be indicated.
Use during pregnancy, lactation or lay
Can be used during pregnancy.
Do not administer in conjunction with other intranasal treatments or during antibiotic treatment.
Safety and efficacy data are available which demonstrate that this vaccine can be administered on the same day, but not mixed, with the live vaccines of the Nobivac series against canine distemper, canine contagious hepatitis caused by canine adenovirus type 1, canine parvovirus disease and respiratory disease caused by canine adenovirus type 2, where authorised, and inactivated vaccines of the Nobivac series against canine leptospirosis caused by all or some of the following serovars: L. interrogans serogroup Canicola serovar Canicola, L. interrogans serogroup Icterohaemorrhagiae serovar Copenhageni, L. interrogans serogroup Australis serovar Bratislava, and L. kirschneri serogroup Grippotyphosa serovar Bananal/Liangguang.
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
In case antibiotics are administered within one week after vaccination, the vaccination should be repeated after the antibiotic treatment is finished.
Amounts to be administered and administration route
Allow the sterile diluent provided to reach room temperature (15 - 25°C). Aseptically reconstitute the freeze-dried vaccine with the diluent. Shake well after addition of the diluent. Remove the needle and administer 0.4 ml directly from the tip of the syringe into one nostril.
Dogs should be at least 3 weeks of age. When Nobivac KC is concurrently administered (i.e. not mixed) with another vaccine of the Nobivac series as indicated under section "Interactions", dogs should not be younger than the minimum age recommended for the other Nobivac vaccine.
Unvaccinated dogs should receive one dose at least 3 weeks prior to the period of anticipated risk, e.g. temporary kennelling, in order to get protection for both vaccine agents. In order to get protection for Bordetella bronchiseptica unvaccinated dogs should receive one dose at least 72 hours prior to the period of anticipated risk (see also section "Special precautions for use").
Particularly in very young puppies, signs of upper respiratory tract disease may occur after an overdose, including ocular and nasal discharges, pharyngitis, sneezing and coughing. The signs may start the day after vaccination and have been seen for up to 4 weeks after vaccination.